Loading stock data…
X4 Pharmaceuticals (XFOR)
$3.50-0.54 (-13.24%)
Market ClosedLast close Sep 8
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
X4 Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.50 with a market capitalization of $379M. Wall Street consensus targets $11.60 (5 analysts), implying a +231.0% move over the next 12 months. The stock is currently 27% below its 52-week high of $4.83, remaining 11.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +231.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 20) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.71M↑ | $2.57M↑ | $1.76M↓ | $1.97M↓ | $28.81M |
| Gross Profit | $2.11M↓ | $2.20M↑ | $1.41M↓ | $1.65M↓ | $24.09M |
| Operating Income | -$20.31M↑ | -$23.70M↑ | -$27.51M↓ | -$26.23M↓ | -$9.44M |
| Net Income | -$20.24M↑ | -$23.93M↑ | -$29.82M↓ | -$25.74M↓ | $282,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$379.17M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-59.20%
Volume
Today's trading volume
2.31M
Recent News
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why
X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress
X4 Pharmaceuticals has seen its modeled fair value price target move from US$8.00 to US$11.67, a sizable uplift that puts more focus on what the current share price is really discounting. Analysts are tying this change closely to expectations around mavorixafor in WHIM syndrome and primary chronic neutropenia, and to how much of that story is already reflected in the stock. As you read on, you will see how different analysts are framing this shift and what to watch as the narrative...
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now
X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.